The Study
Abstract CT082: Phase I study of autologous CD8+ and CD4+ transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal and non-small cell lung cancers with KRAS G12V mutations
This study is like trying to see if a new toy works by giving it to just one kid and watching what happens. You can say what that one kid did, but you can't say if the toy actually works for other kids or if it's better than other toys.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists made T cells that can recognize a rare cancer mutation called KRAS G12V and gave them to patients whose cancers didn't respond to other treatments.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 530 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1It's too early to know if this helps patients — no data exists yet to say whether it works or is safe.
- 2One patient has been treated so far; no results on tumor shrinkage or side effects are available.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Cancer Research
Year
2024
Authors
E. G. Chiorean, A. Coveler, Rachael A Safyan, Stacey Cohen, Sylvia Lee, Cecilia Yeung, Mary Redman, Tom Schmitt, A. Chapuis, Philip D. Greenberg
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.